Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France

Objective: To update the health economic evaluation of pirfenidone in the treatment of idiopathic pulmonary fibrosis (IPF) compared to all available alternatives strategies (Best supportive care – BSC and nintedanib), based on a cost-utility model previously validated by the CEESP’s (French Committe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Emilie Clay, Olivier Cristeau, Romain Chafaie, Alexandrina Pinta, Benjamin Mazaleyrat, Vincent Cottin
Format:	Article
Language:	English
Published:	MDPI AG 2019-01-01
Series:	Journal of Market Access & Health Policy
Subjects:	pirfenidone nintedanib idiopathic pulmonary fibrosis health-economic model cost-effectiveness france ceesp esbriet ofev cost-utility
Online Access:	http://dx.doi.org/10.1080/20016689.2019.1626171
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study
by: Olcay Aycicek, et al.
Published: (2025-02-01)

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01)

Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland
by: Sebastian Majewski, et al.
Published: (2025-06-01)

Treatable traits in idiopathic pulmonary fibrosis: focus on respiratory tract infections—a systematic review and a meta-analysisResearch in context
by: Zsombor Matics, et al.
Published: (2025-01-01)

The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
by: Stefano Kette, et al.
Published: (2025-03-01)

Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis
by: Nesrin Ocal, et al.

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases
by: Tao Wang, et al.
Published: (2025-04-01)

Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis
by: Yiting Qiu, et al.
Published: (2025-07-01)

Perioperative Anti-Fibrotic Treatment Prevents Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Lung Cancer Surgery
by: Stefano Bongiolatti, et al.
Published: (2024-11-01)

Acneiform drug eruption from pirfenidone
by: Jordyn Puccio, BS, et al.
Published: (2025-07-01)

Pulmonary fibrosis complicated by lung cancer: bibliometric analysis from 2004 to 2024 - research status, trends and future directions
by: Boyang Li, et al.
Published: (2025-04-01)

Prevention and Treatment of Peritoneal Dialysis-Associated Fibrosis with Intraperitoneal Anti-Fibrotic Therapy in Experimental Peritoneal Fibrosis
by: Chiao-Yin Sun, et al.
Published: (2025-01-01)

The pulmoprotective effects of pirfenidone against paraquat-induced pulmonary toxicity: a systematic review
by: Sajjad Sadeghi, et al.
Published: (2025-06-01)

Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis
by: Jingran Xu, et al.
Published: (2025-08-01)

INTERSTITIAL LUNG DISEASES: KEY TARGETS FOR THERAPY
by: N. A. Shostak, et al.
Published: (2018-06-01)

Impact of Pirfenidone on Patient-Reported Outcomes in Patients With Idiopathic Pulmonary Fibrosis From the Pulmonary Fibrosis Foundation Patient RegistryTake-home Points
by: Mohleen Kang, MD, MS, et al.
Published: (2024-12-01)

The updated evidence of pirfenidone treated silicosis based on network pharmacology, molecular docking and experimental validation
by: Sirong Chang, et al.
Published: (2025-05-01)

The unexplored mechanism of antitumoral effect of pirfenidone in melanoma cells
by: Melissa Marchese, et al.
Published: (2025-08-01)

A clinical case of idiopathic pulmonary fibrosis against the background of comorbid pathology
by: A. V. Teteneva, et al.
Published: (2021-10-01)

Successful Tepotinib Treatment in MET Exon 14 Skipping Mutation‐Positive Lung Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through Nintedanib Combination
by: Yoshiki Kato, et al.
Published: (2025-06-01)

Trajectory of bodyweight and skeletal muscle mass in patients treated with nintedanib for idiopathic pulmonary fibrosis
by: Hiromi Tomioka, et al.
Published: (2024-12-01)

Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report
by: María Espinosa Bosch, et al.
Published: (2016-07-01)

Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone
by: Tomohiko Yagi, et al.
Published: (2025-02-01)

Affinity of Nintedanib Towards New Candidate Target for Idiopathic Pulmonary Fibrosis
by: Hari Baskar Balasubramanian, et al.
Published: (2024-08-01)

Pirfenidone reduces ovarian fibrosis and improves PCOS in letrozole-induced rat model
by: Ayşe Çakır Gündoğdu, et al.
Published: (2025-06-01)

Evaluation of Safety of a Newly Formulated Pirfenidone in Chronic Kidney Disease: A Non-Randomized Pilot Study in Mexican Patients
by: Simón A. Ojeda-Duran, et al.
Published: (2020-05-01)

Air trapping in patients with idiopathic pulmonary fibrosis: a retrospective case—control study
by: Taehun Kim, et al.
Published: (2025-02-01)

Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France – the POP study
by: A. P. Villani, et al.
Published: (2023-12-01)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
by: Mondher Toumi, et al.
Published: (2017-01-01)

PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS
by: K. Simpson, et al.
Published: (2012-08-01)

Design, development, and preclinical evaluation of pirfenidone-loaded nanostructured lipid carriers for pulmonary delivery
by: Ananda Kumar Chettupalli, et al.
Published: (2025-04-01)

Pirfenidone Alleviates Against Fine Particulate Matter-Induced Pulmonary Fibrosis Modulating via TGF-β1/TAK1/MKK3/p38 MAPK Signaling Pathway in Rats
by: Jun-Seok Sung, et al.
Published: (2025-04-01)

Pharmacoeconomic Analysis of the Use of Thrombopoietin Receptors Agonists in Idiopathic Thrombocytopenic Purpura Therapy
by: VA Shuvaev, et al.
Published: (2017-10-01)

Combination Treatment of Timosaponin BII and Pirfenidone Attenuated Pulmonary Fibrosis Through Anti-Inflammatory and Anti-Fibrotic Process in Rodent Pulmonary Fibrosis Model and Cellular Epithelial–Mesenchymal Transition Model
by: Xuebin Shen, et al.
Published: (2025-04-01)

Comparative efficacy of Pirfenidone and Meloxicam on early radiotherapy-induced anal sphincter dysfunction in rats
by: Dragoș Viorel Scripcariu, et al.
Published: (2025-03-01)

Cost-Effectiveness Analysis of Expanding Influenza Vaccination to Adults Aged 50 and Over in France
by: Guillaume Béraud, et al.
Published: (2025-06-01)

Economic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride Initiation
by: Paul Feuerstadt, et al.
Published: (2025-01-01)

The societal burden associated with adolescent idiopathic scoliosis: a cross-sectional burden-of-disease study
by: Thomáy-Claire Ayala Hoelen, et al.
Published: (2024-11-01)

Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data
by: Jean-Baptiste Arnoux, et al.
Published: (2024-12-01)

Cost-effectiveness of infant hypoallergenic formulas to manage cow’s milk protein allergy in France
by: Ana Teresa Paquete, et al.
Published: (2023-12-01)